| 3.23 0.26 (8.75%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.95  |
1-year : | 4.62 |
| Resists | First : | 3.39 |
Second : | 3.95 |
| Pivot price | 2.57 |
|||
| Supports | First : | 2.54 |
Second : | 2.01 |
| MAs | MA(5) : | 3.08 |
MA(20) : | 2.52 |
| MA(100) : | 2.08 |
MA(250) : | 1.07 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 83.5  |
D(3) : | 87.7 |
| RSI | RSI(14): 63.9 |
|||
| 52-week | High : | 3.5 | Low : | 0.12 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TOI ] has closed below upper band by 8.3%. Bollinger Bands are 66.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.39 - 3.41 | 3.41 - 3.42 |
| Low: | 3.09 - 3.1 | 3.1 - 3.11 |
| Close: | 3.2 - 3.23 | 3.23 - 3.25 |
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Wed, 16 Jul 2025
The Oncology Institute stock initiated with Buy rating at B.Riley By Investing.com - Investing.com South Africa
Tue, 15 Jul 2025
The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 30% But Many Are Still Ignoring The Company - simplywall.st
Mon, 14 Jul 2025
Oncology Institute Names new Chief Administrative Officer - MarketScreener
Mon, 14 Jul 2025
The Oncology Institute Names Kristin England as Chief Administrative Officer - GlobeNewswire
Mon, 14 Jul 2025
Former McKesson US Oncology Leader Joins Oncology Institute to Drive National Growth Strategy - Stock Titan
Sat, 12 Jul 2025
Oncology Institute (NASDAQ:TOI) pops 24% this week, taking one-year gains to 566% - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 92 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 9.2 (%) |
| Held by Institutions | 34.6 (%) |
| Shares Short | 2,410 (K) |
| Shares Short P.Month | 1,870 (K) |
| EPS | -0.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | -16 % |
| Operating Margin | -9.5 % |
| Return on Assets (ttm) | -17.7 % |
| Return on Equity (ttm) | -277.7 % |
| Qtrly Rev. Growth | 10.3 % |
| Gross Profit (p.s.) | 0.64 |
| Sales Per Share | 4.38 |
| EBITDA (p.s.) | -0.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -4.62 |
| PEG Ratio | 0 |
| Price to Book value | 53.83 |
| Price to Sales | 0.73 |
| Price to Cash Flow | -18.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|